New Issue: France’s CAB prices €350 million 3 3/8% notes due 2028

By Rebecca Melvin

Concord, N.H., Nov. 3 – CAB SAS has priced €350 million 3 3/8% notes due 2028 at 98.5001, according to a London Stock Exchange notice on Wednesday.

The notes on the issue date will be senior obligations of CAB and guaranteed on a senior basis by Laboratoire Eimer, Bio Lam LCD, Biomer, BPO-Bioépine, LBM Bioesterel, Astralab, Laborizon Maine Anjou, Laborizon Bretagne, Laborizon Centre, Unilians Biogroup, Biosynergie, Medisch Labo Medina BV, Macsys NV and Centrum voor Medische Analyse BV.

Natixis SA was stabilization manager of the Regulation S deal.

Laboratoire Eimer is the top entity that indirectly owns the French lab testing group CAB.

Issuer:	CAB SAS
Guarantors:	Laboratoire Eimer, Bio Lam LCD, Biomer, BPO-Bioepine, LBM Bioesterel, Astralab, Laborizon Maine Anjou, Laborizon Bretagne, Laborizon Centre, Unilians Biogroup, Biosynergie, Medisch Labo Medina BV, Macsys NV and Centrum voor Medische Analyse BV
Issue:	Notes
Amount:	€350 million
Maturity:	2028
Stabilization manager:	Natixis
Coupon:	3 3/8%
Price:	98.5001
Announcement date:	Nov. 3
Distribution:	Regulation S

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.